Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Emvododstat is an inhibitor of dihydroorotate dehydrogenase (DHODH).1 It inhibits DHODH by 89% in HeLa cells when used at a concentration of 100 nM. Emvododstat inhibits hypoxia-induced VEGF-A synthesis in HeLa cells (EC50 = 1.64 nM). It inhibits viral replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hepatitis C virus (HCV) replicon genotype 1b, poliomyelitis virus, Rift Valley fever (RVF) virus, and Ebola virus in Vero, Huh7, HeLa, HeLa, and Vero 76 cells, respectively (EC50s = 2.6, 36, 0.57, 13, and 9.1 nM, respectively).2 Emvododstat inhibits production of IL-17F and IL-17A induced by CD3 and CD28 in Th17 cells in a concentration-dependent manner.
WARNING This product is not for human or veterinary use.
1. Targeting of hematologic malignancies with PTC299, a novel potent inhibitor of dihydroorotate dehydrogenase with favorable pharmaceutical properties. Mol. Cancer Ther. 18(1), 3-16 (2019).
2. The DHODH inhibitor PTC299 arrests SARS-